EU/3/16/1695

About

Please note that this product was withdrawn from the Union Register of orphan medicinal products in May 2020 on request of the sponsor.

On 14 July 2016, orphan designation (EU/3/16/1695) was granted by the European Commission to Cell Medica Ltd., United Kingdom, for autologous Epstein-Barr virus specific T cells derived from peripheral blood mononuclear cells, expanded ex vivo for the treatment of extranodal NK/T-cell lymphoma, nasal type.

The sponsorship was transferred to Clinical Network Services (NL) B.V., Netherlands, in February 2019.

Key facts

Active substance
Autologous Epstein-Barr virus specific T cells derived from peripheral blood mononuclear cells, expanded ex vivo-
Disease / condition
Treatment of extranodal NK/T-cell lymphoma, nasal type
Date of first decision
14/07/2016
Outcome
Withdrawn
EU designation number
EU/3/16/1695

Review of designation

The Committee for Orphan Medicinal Products reviews the orphan designation of a product if it is approved for marketing authorisation.

Sponsor's contact details

Clinical Network Services (NL) B.V.
De Cuserstraat 93
1081 CN Amsterdam
Noord-Holland
The Netherlands
Tel. +31 2089 49169
E-mail: cns@clinical.net.au

Patients' organisations

For contact details of patients’ organisations whose activities are targeted at rare diseases, see:

  • European Organisation for Rare Diseases (EURORDIS), a non-governmental alliance of patient organisations and individuals active in the field of rare diseases.

  • Orphanet, a database containing information on rare diseases, which includes a directory of patients’ organisations registered in Europe.

How useful was this page?

Add your rating